Reviewing Chromocell Therapeutics (CHRO) and Its Rivals

Chromocell Therapeutics (NYSE:CHRO) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare Chromocell Therapeutics to similar businesses based on the strength of its dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.

Institutional and Insider Ownership

78.0% of Chromocell Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 16.4% of Chromocell Therapeutics shares are owned by insiders. Comparatively, 15.6% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Chromocell Therapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Chromocell Therapeutics	N/A	-$7.38 million	-0.75
Chromocell Therapeutics Competitors	$580.44 million	-$70.96 million	-1.66

Chromocell Therapeutics’ competitors have higher revenue, but lower earnings than Chromocell Therapeutics. Chromocell Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Chromocell Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chromocell Therapeutics	0	0	1	0	3.00
Chromocell Therapeutics Competitors	1992	5500	14154	309	2.58

As a group, “Biological products, except diagnostic” companies have a potential upside of 135.84%. Given Chromocell Therapeutics’ competitors higher probable upside, analysts clearly believe Chromocell Therapeutics has less favorable growth aspects than its competitors.

Profitability

This table compares Chromocell Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Chromocell Therapeutics	N/A	N/A	-453.90%
Chromocell Therapeutics Competitors	-2,185.76%	-161.46%	-40.62%

Volatility and Risk

Chromocell Therapeutics has a beta of 4.59, suggesting that its share price is 359% more volatile than the S&P 500. Comparatively, Chromocell Therapeutics’ competitors have a beta of -4.57, suggesting that their average share price is 557% less volatile than the S&P 500.

Summary

Chromocell Therapeutics beats its competitors on 9 of the 13 factors compared.

About Chromocell Therapeutics

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.